Alkermes outlined plans to move its NT1 drug candidate, alixorexton, into phase 3 after posting results from the midstage ...

Omega Funds has raised $647 million for the investment shop’s latest round aimed at life sciences companies targeting unmet ...

Berkeley is getting a boost, launching a dedicated space for expanding companies that have outgrown their starter homes. | A biotech incubator at the University of California, Berkeley is getting a ...

Roche’s hopes of getting its chronic obstructive pulmonary disease (COPD) drug astegolimab to regulators this year have taken ...

With its Poolbeg Pharma merger plans having bitten the dust and key assets sold off to Gilead, Hookipa Pharma has decided ...

Sail Biomedicines is shrinking its crew for the second time this year. | Sail Biomedicines is shrinking its crew for the ...

Heartflow is once again looking for a path to go public, with a filing for a Nasdaq IPO. | The former Fierce Medtech Fierce ...

On an investor call Friday, analysts grilled the company over its apparent lack of transparency on the matter.

Reeling from the deaths of two patients who took Duchenne muscular dystrophy gene therapy Elevidys, Sarepta is launching a ...

Kennedy Jr. has downplayed the effectiveness of the long-used vaccine and instead promoted the development of new treatments ...

The U.K. is establishing a new biosecurity center designed to improve research into potentially pandemic-causing pathogens ...

Abbott is doubling down on the structural heart space as it aims to gain ground in valve replacements following the recent ...